Verastem's assets, Avutometinib and Defactinib, show promising results in treating KRAS-mutated LGSOC. Read why VSTM stock is a Hold.
Trump pushes ahead with tariffs as stock market have ‘worst day of 2025’ amid recession fears: Live updates - Ontario puts in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback